|
RAB27A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
3.83840000000024E-05 |
| Normal-vs-Stage3 |
1.62436730732907E-12 |
| Normal-vs-Stage4 |
1.62592161956354E-12 |
| Stage1-vs-Stage2 |
1.783630E-01 |
| Stage1-vs-Stage3 |
3.370200E-01 |
| Stage1-vs-Stage4 |
6.412200E-01 |
| Stage2-vs-Stage3 |
3.992000E-01 |
| Stage2-vs-Stage4 |
1.260410E-01 |
| Stage3-vs-Stage4 |
2.335800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62436730732907E-12 |
| Normal-vs-AfricanAmerican |
9.26730000516685E-08 |
| Normal-vs-Asian |
5.64193136654012E-12 |
| Caucasian-vs-AfricanAmerican |
1.027990E-01 |
| Caucasian-vs-Asian |
3.494600E-01 |
| AfricanAmerican-vs-Asian |
4.444600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
1.026310E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(41-60Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(61-80Yrs) |
5.19584375524573E-14 |
| Normal-vs-Age(81-100Yrs) |
5.496100E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.612100E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.845600E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.605600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.870600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.775200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.225600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.982000E-01 |
| Classical-VS-Follicular |
6.78989999780555E-08 |
| Classical-VS-Other |
7.412100E-02 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
9.8692999999983E-05 |
| Tall-VS-Other |
1.985700E-02 |
| Tall-VS-Normal |
1.64412927716739E-12 |
| Follicular-VS-Other |
9.801200E-01 |
| Follicular-VS-Normal |
1.85500004246109E-09 |
| Other-VS-Normal |
3.916100E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.62436730732907E-12 |
| Normal-vs-N1 |
1.7554846465373E-12 |
| N0-vs-N1 |
1.718790E-01 |
|
|
